Benralizumab phase II COPD study published in the Lancet Respiratory Medicine

Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International CongressAstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease (COPD). The study, conducted by MedImmune, the company’s global biologics research and development arm, evaluated the safety and efficacy of benralizumab in 101 adults with moderate-to-severe COPD and